AZTA vs MD

AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.

Pediatrix Medical Group (MD) presents a complex profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company is significantly undervalued on a relative basis (P/E 11.50 vs Sector 73.97) and shows a highly attractive PEG ratio of 0.24, these fundamentals are countered by negative revenue growth (-1.70%) and bearish insider activity. The stock is currently trading near its Graham Number ($21.60), suggesting it is fairly valued from a defensive standpoint, despite a much higher growth-based intrinsic value of $46.75.